NCT03824119

Brief Summary

Previous studies have suggested that NSAID use causes an increase in blood pressure. Further, blood pressure elevation has been noted in women with pregnancy related hypertensive disease during the postpartum period. NSAIDs remain part of standard postpartum care in women with hypertensive disease. The objective of this study is to determine whether postpartum standard care withholding NSAID use is associated with a clinically significant reduction in postpartum hypertension in women with pregnancy induced hypertension. The investigators hypothesize that women with pregnancy induced hypertensive disease will be half as likely to have blood pressure elevation of 150/100 mmHg in the first 24 hours postpartum. This study is an open label randomized trial of women with antepartum hypertension. Women will be randomized to receive standard postpartum care or standard postpartum care without NSAIDs. Blood pressure measurements and patient outcomes will be recorded. The study period will begin at the time of delivery and will end at the time of hospital discharge.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Dec 2018

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 11, 2018

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

January 4, 2019

Completed
27 days until next milestone

First Posted

Study publicly available on registry

January 31, 2019

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 11, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 11, 2022

Completed
Last Updated

November 6, 2020

Status Verified

November 1, 2020

Enrollment Period

4 years

First QC Date

January 4, 2019

Last Update Submit

November 4, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Proportion of participants with blood pressure elevation

    Incidence of Systolic Blood Pressure of 150 mmHg or Diastolic Blood Pressure of 100 mmHg or above

    24 hours postpartum

Secondary Outcomes (9)

  • Proportion of participants with blood pressure elevation

    48, 72 and 96 hours postpartum

  • Number of participants with eclamptic Seizure

    Through study completion, up to 6 weeks postpartum

  • Number of participants with stroke

    Through study completion, up to 6 weeks postpartum

  • Initiation of anti-hypertensive medication

    Randomization through hospital discharge, an average of 3-7 days

  • Pain numerical rating scale (NRS) score

    Randomization through hospital discharge, measured daily, an average of 3-7 days

  • +4 more secondary outcomes

Study Arms (2)

Standard Postpartum Care

ACTIVE COMPARATOR

Subjects will receive NSAIDs (e.g. ibuprofen, ketorolac) for routine postpartum pain management.

Drug: Ibuprofen 600 mg

Standard Postpartum Care without NSAIDs

ACTIVE COMPARATOR

Subjects will receive standard postpartum care without NSAID administration for pain management. Acetaminophen or narcotics will be substituted for ibuprofen as indicated by provider.

Other: Standard Postpartum Care without NSAIDs

Interventions

Standard postpartum care (including administration of NSAIDs)

Also known as: Standard Postpartum Care
Standard Postpartum Care

NSAID administration will be withheld from this group.

Standard Postpartum Care without NSAIDs

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women 18 years or older delivering at LAC/USC Hospital
  • Delivery occurring at or after 20 weeks gestation
  • Diagnosis of antenatal hypertensive disorder: gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia, eclampsia, chronic hypertension

You may not qualify if:

  • HELLP Syndrome
  • Renal dysfunction (Serum Creatinine \>1.1 in current pregnancy)
  • Known liver disease
  • Low platelet count (\<50,000 during hospital admission)
  • Known sensitivity or allergy to ibuprofen or acetaminophen
  • Use of therapeutic doses of anticoagulation
  • Postpartum hemorrhage requiring blood transfusion
  • Neonate with platelet disorder or thrombocytopenia in breastfeeding mother

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

LA County Hospital/University of Southern California

Los Angeles, California, 90033, United States

RECRUITING

Related Publications (11)

  • Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993 Feb 22;153(4):477-84.

    PMID: 8435027BACKGROUND
  • Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994 Aug 15;121(4):289-300. doi: 10.7326/0003-4819-121-4-199408150-00011.

    PMID: 8037411BACKGROUND
  • Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002 Oct 28;162(19):2204-8. doi: 10.1001/archinte.162.19.2204.

    PMID: 12390063BACKGROUND
  • Makris A, Thornton C, Hennessy A. Postpartum hypertension and nonsteroidal analgesia. Am J Obstet Gynecol. 2004 Feb;190(2):577-8. doi: 10.1016/j.ajog.2003.08.030.

    PMID: 14981414BACKGROUND
  • Schoenfeld A, Freedman S, Hod M, Ovadia Y. Antagonism of antihypertensive drug therapy in pregnancy by indomethacin? Am J Obstet Gynecol. 1989 Nov;161(5):1204-5. doi: 10.1016/0002-9378(89)90666-2.

    PMID: 2589441BACKGROUND
  • Wasden SW, Ragsdale ES, Chasen ST, Skupski DW. Impact of non-steroidal anti-inflammatory drugs on hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014 Oct;4(4):259-63. doi: 10.1016/j.preghy.2014.06.001. Epub 2014 Jul 11.

    PMID: 26104814BACKGROUND
  • Viteri OA, England JA, Alrais MA, Lash KA, Villegas MI, Ashimi Balogun OA, Chauhan SP, Sibai BM. Association of Nonsteroidal Antiinflammatory Drugs and Postpartum Hypertension in Women With Preeclampsia With Severe Features. Obstet Gynecol. 2017 Oct;130(4):830-835. doi: 10.1097/AOG.0000000000002247.

    PMID: 28885417BACKGROUND
  • Vigil-De Gracia P, Solis V, Ortega N. Ibuprofen versus acetaminophen as a post-partum analgesic for women with severe pre-eclampsia: randomized clinical study. J Matern Fetal Neonatal Med. 2017 Jun;30(11):1279-1282. doi: 10.1080/14767058.2016.1210599. Epub 2016 Aug 2.

    PMID: 27384376BACKGROUND
  • Walters BN, Thompson ME, Lee A, de Swiet M. Blood pressure in the puerperium. Clin Sci (Lond). 1986 Nov;71(5):589-94. doi: 10.1042/cs0710589.

    PMID: 3769407BACKGROUND
  • Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88. No abstract available.

    PMID: 24150027BACKGROUND
  • Sibai BM. Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol. 2012 Jun;206(6):470-5. doi: 10.1016/j.ajog.2011.09.002. Epub 2011 Sep 16.

    PMID: 21963308BACKGROUND

MeSH Terms

Conditions

Pre-EclampsiaHypertension, Pregnancy-Induced

Interventions

IbuprofenAnti-Inflammatory Agents, Non-Steroidal

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesHypertensionVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

PhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsAnalgesics, Non-NarcoticAnalgesicsSensory System AgentsPeripheral Nervous System AgentsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesAnti-Inflammatory AgentsTherapeutic UsesAntirheumatic Agents

Study Officials

  • Richard Lee, MD

    University of Southern California

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 4, 2019

First Posted

January 31, 2019

Study Start

December 11, 2018

Primary Completion

December 11, 2022

Study Completion

December 11, 2022

Last Updated

November 6, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations